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Abstract 
Background: B Cell Precursor Acute Lymphoblastic Leukemia (BCP‑ALL) is the most common pediatric cancer. Iden‑
tifying key players involved in proliferation of BCP‑ALL cells is crucial to propose new therapeutic targets. Runt Related 
Transcription Factor 1 (RUNX1) and Core‑Binding Factor Runt Domain Alpha Subunit 2 Translocated To 3 (CBFA2T3, 
ETO2, MTG16) are master regulators of hematopoiesis and are implicated in leukemia.
Methods: We worked with BCP‑ALL mononuclear bone marrow patients’ cells and BCP‑ALL cell lines, and performed 
Chromatin Immunoprecipitations followed by Sequencing (ChIP‑Seq), co‑immunoprecipitations (co‑IP), proximity 
ligation assays (PLA), luciferase reporter assays and mouse xenograft models.
Results: We demonstrated that CBFA2T3 transcript levels correlate with RUNX1 expression in the pediatric t(12;21) 
ETV6-RUNX1 BCP‑ALL. By ChIP‑Seq in BCP‑ALL patients’ cells and cell lines, we found that RUNX1 is recruited on its 
promoter and on an enhancer of CBFA2T3 located − 2 kb upstream CBFA2T3 promoter and that, subsequently, the 
transcription factor RUNX1 drives both RUNX1 and CBFA2T3 expression. We demonstrated that, mechanistically, 
RUNX1 and CBFA2T3 can be part of the same complex allowing CBFA2T3 to strongly potentiate the activity of the 
transcription factor RUNX1. Finally, we characterized a CBFA2T3‑mimicking peptide that inhibits the interaction 
between RUNX1 and CBFA2T3, abrogating the activity of this transcription complex and reducing BCP‑ALL lympho‑
blast proliferation.
Conclusions: Altogether, our findings reveal a novel and important activation loop between the transcription regu‑
lator CBFA2T3 and the transcription factor RUNX1 that promotes BCP‑ALL proliferation, supporting the development 
of an innovative therapeutic approach based on the NHR2 subdomain of CBFA2T3 protein.
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Highlights
• The transcription factor RUNX1 and the transcrip-
tion regulator CBFA2T3 interact.
• RUNX1 is recruited on its promoter and on an 
enhancer of CBFA2T3 located − 2  kb upstream 
CBFA2T3 promoter and drives both CBFA2T3 and 
RUNX1 expression.
• CBFA2T3 strongly enhances the transcriptional 
activity of RUNX1.
• A CBFA2T3-truncated protein functions as a potent 
inhibitor of RUNX1 and CBFA2T3 protein–protein 
interaction.
• A CBFA2T3-truncated protein dramatically inhibits 
RUNX1 transcriptional activity and decreases BCP-
ALL lymphoblast proliferation.
• The RUNX1 and CBFA2T3 self-activation loop is a 
BCP-ALL driver loop.
Background
RUNX1 (Runt Related Transcription Factor 1) is a major 
transcription factor of hematopoiesis. It belongs to 
the RUNX family of transcriptional regulators, where 
members, RUNX1, RUNX2 and RUNX3, share a Runt 
domain that shows strong evolutionary conservation [1] 
and is responsible for DNA binding. RUNX1 is essen-
tial for definitive hematopoiesis in early development 
as well as in adulthood for megakaryocyte maturation, 
T- and B-cell lineage and neuronal development [2–5]. 
RUNX1 gene deregulation, either by genetic alterations 
(point mutation or chromosome abnormalities) or gene 
expression modification, is involved in many hematologi-
cal malignancies, notably in ETV6-RUNX1 pre-B acute 
lymphoblastic leukemia (BCP-ALL) [6–9]. The transcrip-
tional activity of RUNX1 depends on its hetero-dimeri-
zation with the non-DNA binding factor CBFβ, and on 
the recruitment of co-factors [10] that bind functional 
domains that negatively or positively modulate RUNX1 
transcriptional activity [11].
CBFA2T3 (Core-Binding Factor Runt Domain Alpha 
Subunit 2 Translocated To 3, also known as MTG16, 
ETO2) belongs to the eight-twenty-one (ETO) family of 
chromatin-associated proteins. This family also includes 
Myeloid Translocation Gene 1-Related (MTGR1) and 
Myeloid Translocation Gene 8 (MTG8, ETO) [12]. Each 
of these proteins contains four Nervy Homology Region 
(NHR) domains, and form homo- or hetero-oligomeric 
ETO complexes via the NHR2 domain [13, 14]. CBFA2T3 
is important for hematopoietic stem and progenitor cells 
self-renewal, lineage commitment and differentiated 
hematopoietic lineages including T-cell development 
or erythropoiesis [15–17]. CBFA2T3 participates in 
oncogenic recurrent translocations in acute myeloid 
leukemia (with the t(16;21)(q24;q22) giving rise to 
RUNX1-CBFA2T3) or acute megakaryoblastic leukemia 
(with inv [16] (p13q24) giving rise to CBFA2T3-GLIS2) 
[17]. Numerous binding partners have been reported for 
CBFA2T3, including transcription factors and chromatin 
modifiers[17], and it is generally believed that the ETO 
family members act as transcriptional repressor proteins 
via multiple binding to corepressors, such as nuclear 
receptor corepressor (NCOR), silencing-mediator for 
retinoid/thyroid hormone receptor (SMRT), mSin3a, and 
histone deacetylases (HDACs) [12, 18].
BCP-ALL is the most frequent type of pediatric can-
cer. Several detailed studies have examined the expres-
sion of genes deregulated in ETV6-RUNX1 BCP-ALL 
compared to other types of leukemia and demonstrated 
that RUNX1 and CBFA2T3 are specifically upregulated 
in ETV6-RUNX1 BCP-ALL [19] suggesting that these 
genes could be implicated in the onset and the mainte-
nance of BCP-ALL [19–21]. Moreover, the RUNX1 and 
CBFA2T3 proteins were previously identified as potential 
partners in erythroid cells or in an overexpression model 
in HEK293T cells [22–24].
In this study, we aimed at delineating the functional 
and structural CBFA2T3 and RUNX1 relationship at the 
genome and protein levels. First, we demonstrated that 
RUNX1 protein upregulates CBFA2T3 gene. Next, we 
characterized the protein–protein interaction domains 
between CBFA2T3 and RUNX1. At a mechanistic level, 
we identified an activation loop between CBFA2T3 and 
RUNX1. Finally, at a functional level, we demonstrated 
that a CBFA2T3-mimicking peptide, whose expres-
sion was able to disrupt this activation loop by inhibit-
ing RUNX1 activity, results in a decrease of BCP-ALL 
cell proliferation. Our findings reveal a novel BCP-ALL 
driver loop dependent on CBFA2T3 and RUNX1.
Methods
Detailed experimental procedures for RNA extraction, 
RT-qPCR, generation of stable cell lines, luciferase assay, 
immunoblotting, chromatin immunoprecipitation (ChIP-
Seq), ChIP-PCR and cell cycle and apoptosis assays are 
presented in Additional file  1. Lists of primers and pri-
mary antibodies are presented in Additional file 1: Tables 
S1 and S2.
Cell lines and patients’ cells
Pre-B leukemia cell line Nalm6 (ATCC#CRL-3273TM) 
and REH (ATCC#CRL-8286™) were maintained in 
RPMI-1640 medium containing 10% heat-inacti-
vated fetal calf serum and 1% penicillin/streptomycin. 
HEK293 cells (ATCC#CRL-1573TM) were maintained in 
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DMEM/10% fetal calf serum/1% antibiotics. Bone mar-
row cells from B cell precursor acute lymphoblastic leu-
kemia (BCP-ALL) patients, not presenting the t(12;21) 
ETV6-RUNX1 fusion gene, were collected at diagnosis, 
after informed consent had been obtained, in accord-
ance with the declaration of Helsinki. The protocol was 
approved by the ethics committee of Rennes Hospital 
(France).
Generation of stable cell lines and plasmids
REHshCBFA2T3 or  REHshRUNX1 cells were obtained by trans-
duction with lentivirus MISSION pLKO.1 shRNA puro-
mycine or neomycine resistant (#TRCN0000013660; 
TRCN0000358353; TRCN0000416005; TRCN0000020165, 
Sigma-Aldrich). Halotag-ETV6-RUNX1, Halotag-RUNX1 
plasmids are described in [25, 26]. CBFA2T3-myc trun-
cated protein plasmids were provided by Andrew Turner 
and David Callen [27] and subcloned to have Flag-version 
and to allow lentiviral production in pLL3.7 plasmid for 
 REH+NHR2 cell production.
For luciferase assays, genomic DNA fragments 
derived from the human CBFA2T3 (chr16:89,045,181–
89,045,538) or RUNX1 (chr21:36,421,428–36,421,673 
(hg19 coordinates) gene, and RUNX1-consensus motif 
repetition AGA TTT CCA AAC TCTGT GGT TGC CTT 
(three times repeats) as described in [28] were cloned 
into pGL4.10-luc with a minimal promoter. The c-KIT 
enhancer luciferase plasmid is described in [26].
Proximity ligation assay (PLA)
PLA was carried out with Duolink® In  Situ Detection 
Reagents (Sigma Aldrich). PLA technology allows the 
detection of interactions between endogenous proteins, 
based on the detection of protein proximity. PLA uses 
one pair of primary antibodies; each antibody targets 
one of the two distinct proteins for which the proximity 
is studied. The antibodies used for PLA have been vali-
dated by immunofluorescence and western blot. For the 
validation of each PLA experiment, a negative control 
(only one type of antibody) and a positive control (two 
antibodies raised against different epitopes of the same 
protein are used, this corresponds to ‘total CBFA2T3′ 
or ‘total RUNX1′ as indicated in the figure legend) are 
included. The experimental procedure, the automatic 
quantification and analysis of PLA dots per nucleus were 
extensively described in [25] which is a publication dedi-
cated to the validation of PLA method in pre-B lympho-
blasts, especially in non-adherent human pre-B Nalm6 
cells, REH cells and human bone marrow mononuclear 
cells. For the statistical analysis of the results, the cut-off 
for positivity has been set at two standard deviations over 
the mean of the negative control signal as described in 
[25, 29]. To state on the existence or absence of the pro-
tein–protein interaction, we performed an analysis of 
Contingency Table with a Fisher’s exact test comparing 
the number of dots below and above the cut-off. To state 
on the variation of the specific number of protein–pro-
tein interactions we performed a parametric t-test.
Chromatin immunoprecipitation (ChIP) and binding site 
analysis
The detailed procedure is described in Additional file 1. 
The ChIP-Seq performed are: RUNX1 in REH cells 
(n = 2), Nalm6 (n = 2), BCP-ALL patients not expressing 
ETV6-RUNX1 (n = 3), H3K4me1, H3K4me3, H3K27ac, 
and CBFA2T3 in REH (n = 1) and Nalm6 (n = 1). Anti-
bodies used are listed in Table S2. All sequencing data are 
available at NCBI’s GEO (https ://www.ncbi.nlm.nih.gov/
geo/query ) through #GSE109377 for RUNX1 in Nalm6 
and patients[26] and #GSE117684 for the other data.
Co‑immunoprecipitation (Co‑IP) assay
Ten percent (5µL) of protein extracts were separated 
from the rest for the input. The remaining input was 
incubated overnight with anti-Flag magnetic beads (M2 
clone, Sigma M8823) in a total of 1 mL co-IP Lysis Buffer, 
on a rotation wheel at 4  °C according to the manufac-
turer’s recommendations. Ten µL of beads were used for 
each condition, with a binding capacity of 6  µg of pro-
teins. The following day, the beads were washed with 
Tris Buffered Saline (TBS) and the proteins were eluted 
in Laemmli Buffer. Finally, the co-IP samples and their 
respective input were resolved on a 10% polyacrylamide 
gel for Western-Blotting.
Cell proliferation, cell cycle and apoptosis assays
Proliferation assays were done by automatic counting 
with a Cellometer (Nexcelom). Apoptosis assay was done 
using Annexin V-FITC (130-092-052, Miltenyi biotec) 
and Propidium Iodide. For cell cycle analyses, we per-
formed nocodazole block.
Xenograft transplantation and survival analysis
NOD/scid IL2  Rgnull mice (Charles River Laboratories, 
France) were maintained in the ARCHE Animal Hous-
ing Center (Rennes, France). Animal experiments were 
performed after authorization by the French Research 
Ministry, and according to European regulation. Four-
week-old mice received two intraperitoneal injections 
of 20  μg/g busulfan (60  mg/10  mL, Pierre Fabre) on 
2 days. They were then allowed to rest for 2 days before 
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retro-orbital injection of 100,000 cells as previously 
described [30].
Statistical analysis
Statistical analyses were performed with GraphPad 
Prism 6 software. Statistical significance was analyzed 
using Mann–Whitney nonparametric tests for small 
sizes samples, parametric t-test for larger size samples, 
and Fisher’s exact test when appropriate.
Results
CBFA2T3 transcript level is upregulated in blasts 
from BCP‑ALL patients and is correlated with RUNX1 
expression.
Among BCP-ALL subtypes, RUNX1 and CBFA2T3 tran-
scripts are upregulated in ETV6-RUNX1 BCP-ALL blasts 
(Fig. 1a, Additional file 2: Fig. S1A). This result, obtained 
from the analysis of the RNA-Seq database of St. Jude 
Children’s Research Hospital Pediatric Cancer Data Por-
tal cohort [31], is coherent with microarray data from 









































































































































































patients' cells patients' cells
ETV6-RUNX1 BCP-ALL patients BCP-ALL other than ETV6-RUNX1 patients
Fig. 1 RUNX1 and CBFA2T3 mRNA level are positively correlated in ETV6‑RUNX1 BCP‑ALL. a and b The graphs represent the mRNA expression 
level of CBFA2T3 and RUNX1 in human pediatric ETV6‑RUNX1 BCP‑ALL bone marrow mononuclear cells and the other non‑ETV6‑RUNX1 BCP‑ALL 
bone marrow mononuclear cells. Data of mRNA levels (expressed in Fragments Per Kilobase Million—FPKM) have been extracted from the St. 
Jude Children’s Research Hospital RNA‑Seq Pediatric Cancer Data Portal [31]. For a ****p < 0.0001 in t‑test between both conditions, for b a Pearson 
correlation has been performed. ns, non significant. Mean data and numbers of samples (n) are indicated above each graph. c Correlation between 
RUNX1 and CBFA2T3 mRNA levels originating from REH cells and Nalm6 cells that overexpress or are depleted for RUNX1 or CBFA2T3. Statistical 
analysis has been performed using Pearson correlation. n, number of samples per condition
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previous cohorts [19–21]. Moreover, RUNX1 transcript 
level positively and significantly correlates with CBFA2T3 
transcript level in ETV6-RUNX1 BCP-ALL samples com-
pared to other childhood BCP-ALL (Fig. 1b). Neverthe-
less, this correlation between RUNX1 and CBFA2T3 
expression is retrieved under enforced expression or 
depletion of RUNX1 or CBFA2T3 in two BCP-ALL cell 
lines, the REH cells (that express ETV6-RUNX1 tran-
script and protein) and Nalm6 cells (that do not express 
ETV6-RUNX1) (Fig.  1c). First, this result strongly sug-
gests that RUNX1 is involved in CBFA2T3 expression 
and vice versa. Second, it also suggests that this corre-
lation is directly dependent on RUNX1 rather than on 
the presence of ETV6-RUNX1 transcript or protein. We 
therefore hypothesized the existence of a common acti-
vation loop between these two proteins, RUNX1 and 
CBFA2T3, and further investigated their mutual implica-
tion in the control of their transcription and its pheno-
typic consequence.
The transcription factor RUNX1 binds RUNX1 promoter 
and a CBFA2T3 enhancer, autoregulates its expression 
and drives CBFA2T3 expression
CBFA2T3 does not bind DNA but acts as a transcrip-
tional regulator. To investigate whether RUNX1 could 
be recruited to RUNX1 and CBFA2T3 regulatory ele-
ments (promoters or enhancers), we performed chro-
matin immunoprecipitation followed by sequencing 
(ChIP-Seq) with RUNX1 antibody in REH cell line. We 
compared with our previously published ChIP-Seqs 
done in Nalm6 cells [26]. We also performed ChIP-Seq 
with histones H3K4me1 (markers of active enhancers), 
H3K4me3 (active promoters) and H3K27ac (transcrip-
tionally active chromatin) in REH and Nalm6 cells. 
RUNX1 occupied 27 786 sites genome-wide in BCP-ALL 
patients, 5 514 sites in Nalm6 cells with an overlap of 
69% between Nalm6 and patients’ cells [26], 9 621 sites 
in REH cells with an overlap of 60% with Nalm6 and 65% 
with patients (Additional file 2: Fig. S1B). Among those 
peaks, we clearly identified that RUNX1 is recruited on 
its promoter and on an enhancer of CBFA2T3 located 
− 2  kb upstream of CBFA2T3 promoter (Fig.  2a, b). 
These two bound regions are associated with active 
chromatin markers suggesting that they are active regu-
latory elements (Fig. 2a, b).
To confirm the responsiveness of those two RUNX1-
bound regions, one found in RUNX1 promoter and the 
other in the − 2  kb CBFA2T3 enhancer, we performed 
luciferase reporter assays in HEK293 cells overexpressing 
RUNX1 and/or CBFA2T3 (Fig.  2c, d). The result shows 
that overexpressed RUNX1 possibly induces transcrip-
tion from those RUNX1 and CBFA2T3 regulatory ele-
ments. This transcription is abrogated after deletion of 
the putative RUNX1 DNA-binding motif found in both 
regulatory elements, demonstrating the direct implica-
tion of the binding of RUNX1 on chromatin on those 
regions for transcription regulation (Fig. 2c, d).
The transcriptional regulator CBFA2T3 potentiates 
the activity of RUNX1
In order to investigate the consequence of CBFA2T3 pro-
tein in presence of RUNX1 transcription factor, similarly 
to what is observed in BCP-ALL patients’ cells (Fig. 1b) 
and in BCP-ALL cell lines (Fig.  1c), we also tested the 
impact of CBFA2T3 enforced expression with luciferase 
assays in HEK293 cells (Fig. 2c, d). Addition of CBFA2T3 
does not impact transcription, which is consistent with 
its inability to bind DNA. However, when both CBFA2T3 
and RUNX1 proteins are concomitantly expressed, we 
observed a synergistic effect on both regulatory ele-
ments. This cooperative effect is lost when the putative 
RUNX1 DNA-binding sequences are deleted (Fig. 2c, d). 
To definitively ascertain the role of the binding of RUNX1 
on its DNA consensus sequence in this cooperation, we 
used a luciferase assay with a plasmid bearing a tandem 
of RUNX1-consensus binding sequence as published in 
[26, 28]. Again, we observed a synergy between RUNX1 
and CBFA2T3 for the control of RUNX1-induced tran-
scription (Fig.  2e). Whilst the fusion protein ETV6-
RUNX1 overexpression can cooperate with RUNX1 
and CBFA2T3 to activate RUNX1 promoter, it does not 
drastically impact this cooperation between RUNX1 and 
CBFA2T3 neither on CBFA2T3 enhancer nor on the rep-
etition of RUNX1-consensus binding motifs (Additional 
file 2: Fig. S1c–e), confirming the importance of RUNX1 
activity on those regulatory elements over ETV6-RUNX1 
activity.
Altogether, our results demonstrated that CBFA2T3 
can be an activator of RUNX1 transcription factor. No 
additional DNA sequence, other than the RUNX1 DNA-
consensus sequence, seems to be required to observe 
the activation of RUNX1-dependent transcription by 
CBFA2T3. This result orientated us to question the inter-
action between RUNX1 and CBFA2T3 proteins.
RUNX1 and CBFA2T3 proteins interact on chromatin
As CBFA2T3 is neither a transcription factor per se, nor 
a DNA-binding protein, we suspected that RUNX1 could 
act as a platform to recruit CBFA2T3 as a co-factor. To 
look for endogenous protein–protein colocalization, 
we used a Proximity Ligation Assay (PLA) as we had 
applied previously to human pre-B cells [25]. RUNX1 and 
CBFA2T3 endogenous proteins colocalize in the BCP-
ALL cell lines REH and Nalm6, and importantly in BCP-
ALL patients’ bone marrow blasts (Fig. 3a–c; Additional 
file  2: Fig. S1F). The interaction between RUNX1 and 
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CBFA2T3 was further confirmed by co-immunoprecipi-
tation in REH cells on endogenous proteins and HEK293 
cells with tagged-proteins (Fig.  3D). The interaction is 
maintained with the fusion protein ETV6-RUNX1 but 
not with ETV6 demonstrating the role of RUNX1 in this 
interaction over ETV6 (Additional file 2: Fig. S2a–d). This 
suggests that RUNX1 and CBFA2T3 could be part of the 




Fig. 2 RUNX1 and CBFA2T3 interplay for their transcription. a and b ChIP‑Seq profiles across the human RUNX1 (a) and CBFA2T3 (b) genes. Genomic 
tracks display ChIP‑Seq profiles of RUNX1 from REH cells, Nalm6 cells and BCP‑ALL patients, and of the histones H3K27ac, H3K4me3, and H3K4me1 
from REH and Nalm6 cells. RUNX1 ChIP‑Seq from bone marrow mononuclear cells isolated from three pre‑B acute lymphoblastic leukemia patients 
(BCP‑ALL) are also displayed. ChIP‑Seq reads were aligned to the reference human genome version GRCh37 (hg19). Each genomic regions of RUNX1 
and CBFA2T3 genes that are subsequently studied are indicated by boxes. c–e Luciferase assays with a plasmid containing the RUNX1 promoter 
(chr21: 940,581–940,336(C), CBFA2T3 enhancer (chr16:89,045,181–89,045,538) (D) and a repetition of RUNX1‑consensus motif (E) upstream a 
minimal promoter and a luciferase ORF, in presence of RUNX1 and CBFA2T3 expressing plasmids in HEK293 cells. Note that the HEK293 cells do not 
endogenously express RUNX1 and CBFA2T3. Luciferase levels (Firefly luciferase/Renilla luciferase) are represented using a scatter dot plot indicating 
the means and S.D. NS: non‑significant, **p < 0.01, ***p < 0.001, ****p < 0.0001 in Mann–Whitney tests compared to the control condition








Fig. 3 CBFA2T3 and RUNX1 colocalize. a, b, c, e and f Quantitation of protein co‑localization per nucleus and visualized by Proximity Ligation Assay 
(PLA) dots in REH cells (a, e), Nalm6 cells (b, f) and BCP‑ALL patient cells (c), presented with the mean values ± S.D. Antibodies used are indicated 
under each plot. Positive controls (total CBFA2T3, where primary antibodies against two different epitopes of CBFA2T3 were used) and negative 
controls (only one anti‑CBFA2T3) were included. One representative experiment of at least two independent experiments is shown. The data are 
normalized against total CBFA2T3. The mean value is indicated above each plot. The positive threshold value is represented by the dotted line (set 
at two S.D over the background signal as described in [25]). NS: non‑significant, * p < 0.05, **** p < 0.0001 in Fisher’s exact test compared to the 
negative control condition. d Co‑immunoprecipitation (co‑IP) using (left panel) IgG or RUNX1 antibody in REH cells, and (in right panel) anti‑Flag 
antibody in HEK293 cells expressing RUNX1‑Halotag and/or CBFA2T3‑Flag plasmids. Western blots were performed with RUNX1 and CBFA2T3 
antibodies. Molecular weights are indicated on the right. g Density plots of CBFA2T3 Chip‑Seq signals into RUNX1‑bound regions or random 
regions in REH and Nalm6 cells. h ChIP‑Seq profiles across the human CBFA2T3 gene. Genomic tracks display ChIP‑Seq profiles for RUNX1 and 
CBFA2T3 from REH cells. ChIP‑Seq reads were aligned to the reference human genome version GRCh37 (hg19). Two enhancers at + 9 kb and − 2 kb 
have been focused on. i Logo corresponding to the RUNX1 enriched motif for CBFA2T3 regions in REH cells. REH and Nalm6 CBFA2T3 Chip‑Seq 
have been analyzed with the Analysis of Motif Enrichment of the MEME suite [32]. The optimal enrichment p‑value of the motif according to the 
Fisher’s exact test, adjusted for multiple tests using a Bonferroni correction is indicated
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colocalization of CBFA2T3 (Fig. 3e, f ) as well as RUNX1 
(Additional file 2: Fig. S2E-F) with co-repressors such as 
HDAC1, NCOR, and SIN3A as already demonstrated by 
others [13, 18]. Importantly, we also showed that a frac-
tion of RUNX1 and CBFA2T3 colocalize with activators 
including CREBPP (CBP) and EP300 (P300) (Fig.  3e, f, 
Additional file 2: Fig. S2E-F). Altogether, these data show 
that RUNX1 and CBFA2T3 proteins can be part of the 
same complex, and CBFA2T3 possibly plays an activa-
tor role. Whilst CBFA2T3 is not a DNA-binding pro-
tein, we performed CBFA2T3 Chip-Seqs in Nalm6 and 
REH cells. We retrieved 339 CBFA2T3 binding regions 
in Nalm6 and 2639 in REH cells with 47% (158 peaks) of 
the peaks in Nalm6 in common with the REH cells (Addi-
tional file  2: Fig. S2G). We observed that RUNX1 and 
CBFA2T3 Chip-Seqs from REH and Nalm6 cells show 
an enrichment of CBFA2T3 signals in RUNX1-bound 
regions, as well as an enrichment of RUNX1 signals in 
CBFA2T3-bound regions, demonstrating the presence of 
the RUNX1 and CBFA2T3 complex on RUNX1-bound 
chromatin regions (Fig. 3g, Additional file 2: Figure S2H-
I). This is well illustrated in the − 2 kb and + 9 kb enhanc-
ers of CBFA2T3 gene (Fig.  3h), and to a lesser extend 
on the RUNX1 promoter by ChIP-qPCR and ChIP-Seq 
(Additional file  2: Fig. S2J). In total, 5.2% CBFA2T3-
bound regions are in common with the RUNX1-bound 
regions in the REH cells. Concordantly, the RUNX1 
consensus binding sequence ‘BYTGT GGT TWB’ is also 
found significantly enriched, among many others, in 
the CBFA2T3-bound regions in REH and Nalm6 cells 
(Fig. 3i, Additional file 3: Tables S3-S4).
Clearly, not all RUNX1-bound regions are shared with 
CBFA2T3, and not all CBFA2T3-bound regions are 
shared with RUNX1. This result indicates that RUNX1 
and CBFA2T3 are not always in the same complex.
Altogether, our results suggest that a complex between 
RUNX1 and CBFA2T3 can be poised on chromatin to 
regulate, and importantly activate, common target genes 
including RUNX1 and CBFA2T3 genes.
The NHR2 domain of CBFA2T3 is involved in the interaction 
with RUNX1.
We further characterized the interaction domain 
between CBFA2T3 and RUNX1. CBFA2T3 is com-
posed of four functional domains named NHR1 to 4 
(Fig.  4a) [27, 33]. RUNX1 displays a highly conserved 
DNA binding domain (the RUNT domain), followed 
by a transactivation domain (TD) and an inhibitory 
domain (ID) (Fig. 4a). Co-immunoprecipations with sev-
eral CBFA2T3-truncated proteins demonstrated that 
the  CBFA2T3NHR2 domain and the  CBFA2T3NHR3−4 
domain interact with RUNX1 in HEK293 cells (Fig. 4b). 
We also showed that  RUNX1Δ50−175 and to a much lesser 
extend  RUNX1Δ244−322 bind CBFA2T3 suggesting that 
the C-terminal region (aa372-453) is necessary for bind-
ing whereas the RUNT domain and the transactiva-
tion domain of RUNX1 are not crucial for this binding 
(Fig. 4c).
The co-immunoprecipitation of NHR2 and CBFA2T3 
was previously reported [34]. Since the  CBFA2T3NHR2 
domain is able to bind RUNX1 and also functions as 
a tetramerization domain for CBFA2T3, we next con-
firmed that  CBFA2T3NHR2 domain not only interacts 
with CBFA2T3 but also with RUNX1, using proxim-
ity ligation assay in HEK293 cells (Fig.  4d). Altogether, 
our results demonstrated that the NHR2 domain of 
CBFA2T3 directly interacts with RUNX1.
Free NHR2 domain of CBFA2T3 functions as a potent 
inhibitor of endogenous RUNX1 and CBFA2T3 protein 
interaction
ETO belongs to the same family as CBFA2T3 and also 
contains an NHR2 homologous domain. Wichmann 
et al. reported that expression of a 128 amino-acid pep-
tide that includes the NHR2 domain of ETO (NC128) 
blocks the oligomerization of the RUNX1-ETO fusion 
protein [35]. Similarly, we hypothesized that ectopic 
 CBFA2T3NHR2 domain could act as an inhibitor of the 
interaction between RUNX1 and CBFA2T3, since we 
found that  CBFA2T3NHR2 is able to bind RUNX1 as well 
as CBFA2T3. Doing so, we observed that the ectopic 
expression of  CBFA2T3NHR2 inhibits the endogenous 
interaction between RUNX1 and CBFA2T3 as assayed by 
proximity ligation in REH cells (Fig. 5a, Additional file 2: 
Fig. S2J) and also limits the interaction between exog-
enous RUNX1 and CBFA2T3 in HEK293 cells (Fig. 5b). 
Concordantly, by co-immunoprecipitation assay, we 
demonstrated that the presence of  CBFA2T3NHR2 
decreases by half the interaction between RUNX1 and 
CBFA2T3 (Fig.  5c). Altogether, our data demonstrated 
that ectopic NHR2 impedes endogenous RUNX1 and 
CBFA2T3 protein–protein interaction.
The NHR2 domain of CBFA2T3 dramatically inhibits RUNX1 
transcriptional activity
We next questioned the functional impact of the pres-
ence of NHR2 on RUNX1-induced transcription. 
We first tested the  CBFA2T3NHR2 truncated protein 
on the activity of the luciferase plasmid bearing the 
tandem of RUNX1-binding sequence (Fig.  6a). We 
observed that the NHR2 totally abrogates the syner-
gistic cooperation between RUNX1 and CBFA2T3 on 
transcription. Then, we tested whether  CBFA2T3NHR2 
peptide affects transcription of the RUNX1 pro-
moter and CBFA2T3 enhancer (used in Fig.  2c, d), 
and the additional c-KIT enhancer, also reported to 





Fig. 4 The NHR2 domain of CBFA2T3 is involved in the interaction between RUNX1 and CBFA2T3. a Representation of the full‑length and truncated 
CBFA2T3 and RUNX1 proteins used to the functional domain analysis. NHR, Nervy Homology Region; TD, Transactivation domain; ID, inhibitory 
domain. b, c Co‑immunoprecipitation (IP) using anti‑Flag antibody in HEK293 cells expressing various full‑length and truncated proteins for 
CBFA2T3 (b) and RUNX1 (c) described in (a). Western blots were performed with RUNX1, Myc and CBFA2T3 antibodies. Molecular weights are 
indicated on the right. d Quantitation of protein co‑localization per nucleus and visualized by Proximity Ligation Assay (PLA) dots in HEK293 cells 
expressing  CBFA2T3NHR2‑Myc with either RUNX1‑Halotag or CBFA2T3‑Flag, presented with the mean values ± S.D. Antibodies used are anti‑RUNX1, 
anti‑Myc and anti‑Flag. Positive control (total RUNX1) and negative control were included. The data are normalized against total RUNX1. The mean 
value is indicated above each plot. The positive threshold value is represented by the dotted line as described in [25]. ****p < 0.0001 in Fisher’s exact 
test compared to the negative control condition
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be RUNX1-sensitive [26], using luciferase reporter 
assay in HEK293 cells. For these three regulatory ele-
ments, addition of  CBFA2T3NHR2, again, prevents, 
with various amplitudes, the synergistic activity of 
RUNX1 and CBFA2T3 on their transcription (Fig. 6b–
d). Concordantly with the luciferase assay results, 
the RUNX1, CBFA2T3 and c-KIT genes targeted by 
RUNX1 were down-regulated in REH cells expressing 
 CBFA2T3NHR2 (Fig. 6e).
Altogether, these results enable us to propose 
the following model (Fig.  6f ). The upregulation 
of RUNX1 and CBFA2T3 could be explained by a 
cross-activation loop. First, the RUNX1 transcription 
factor participates in CBFA2T3 expression. The tran-
scription regulator CBFA2T3, in return, binds RUNX1 
protein and enhances RUNX1 expression, and there-
fore increases its own expression. We show here that 
CBFA2T3, often described to have a repressive activ-
ity, could also act as co-activator on RUNX1 activity. 
The presence of intracellular NHR2 blocks this cross-
activation loop, by a mechanism that may implicate 



































































































































































Fig. 5 Free NHR2 domain of CBFA2T3 disrupts the protein complex formed by RUNX1 and CBFA2T3. a and b Quantitation of RUNX1 and CBFA2T3 
protein co‑localization per nucleus and visualized by PLA dots in REH cells (a) and HEK293 cells (b) in presence or absence of  CBFA2T3NHR2‑Myc, 
presented with the mean values ± S.D. The mean value is indicated above each plot. The statistical analyses are run with parametric t‑tests. 
*p < 0.1; ****p < 0.0001. The right panel shows a set of pictures of PLA between RUNX1 and CBFA2T3 for HEK293 cells in presence or absence 
of  CBFA2T3NHR2‑Myc. The PLA dots are in purple, nuclei are in blue (DAPI). Bar: 10 um. c Co‑immunoprecipitation (IP) using anti‑Flag antibody 
in HEK293 cells expressing RUNX1‑Halotag, CBFA2T3‑Flag or  CBFA2T3NHR2‑Myc. Western blots were performed with RUNX1, Myc and CBFA2T3 
antibodies. Molecular weights are indicated on the right
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NHR2 subdomain decreases lymphoblast proliferation
We further studied the impact of NHR2 on cell pheno-
type. Depletions of CBFA2T3 and RUNX1 by stable 
shRNA decrease cell proliferation suggesting that RUNX1 
and CBFA2T3 sustain independently cell proliferation in 
leukemic cells (Fig. 7a, Additional file 2: Fig. S3A-B). Cor-
relation between mRNA level of CBFA2T3 or RUNX1 
and the proliferation rate suggests that CBFA2T3 is the 
main regulator of proliferation in BCP-ALL (Additional 
file  2: Fig. S3C). Moreover, the combined depletion of 
CBFA2T3 and RUNX1  (REHshCBFA2T3+shRUNX1 cell line, 
p = 0.0010 compared to  REHcontrol) slows down the pro-
liferation dramatically more than a single depletion of 
either RUNX1 or CBFA2T3  (REHshRUNX1+mock cell line, 
p = 0.0133 compared to  REHcontrol or  REHshCBFA2T3+mock 
cell line, p = 0.0280 compared to  REHcontrol), compatible 
with additive or cooperative effects between RUNX1 and 








































































































































Fig. 6 Free NHR2 domain of CBFA2T3 inhibits the cooperative effect of CBFA2T3 on RUNX1 activity. a–d Luciferase assays with the 
RUNX1‑consensus motif repetition (a), the RUNX1 promoter (b), the CBFA2T3 enhancer (c) and the c‑KIT enhancer (d) upstream a minimal promoter 
and a luciferase ORF, in presence of RUNX1 and CBFA2T3 or  CBFA2T3NHR2 expressing plasmids in HEK293 cells. Luciferase levels (Firefly luciferase/
Renilla luciferase) are represented using a scatter dot plot indicating the means and S.D. ns: non‑significant, **p < 0.01, ***p < 0.001, ****p < 0.0001 
in Mann–Whitney tests compared to the control condition. e Relative mRNA expression of RUNX1, CBFA2T3 and c‑KIT measured by RT‑qPCR in 
REH cells, and REH expressing  CBFA2T3NHR2 cells  (REH+NHR2). Results are presented in‑terms of a fold change after normalizing with ABL mRNA. f 
Schematic representation of the activation loop between RUNX1 and CBFA2T3. Expression of the free NHR2 domain interrupts this loop
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CBFA2T3 is able to rescue half of the proliferation delay 
induced by the depletion of RUNX1  (REHshRUNX1+CBFA2T3 
cell line, non significant compared to  REHcontrol), which 
is compatible with an additive effect. However, the res-
cued expression of RUNX1 is not sufficient to restore 
the proliferation delay induced by depletion of CBFA2T3 
 (REHshCBFA2T3+RUNX1 cell line, p = 0.0286 compared to 
 REHcontrol), demonstrating that RUNX1 and CBFA2T3 
participate into a common pathway, at least partially. 




Fig. 7 Expression of free NHR2 domain of CBFA2T3 delays BCP‑ALL cell proliferation. a and b Proliferation curves from  REHshcontrol,  REHshRUNX1, 
 REHshCBFA2T3−1,  REHshCBFA2T3−2 (a), or  REHshcontrol and  REH+NHR2 cells (b). Three experiments are represented for each condition. For more readability, 
statistical analyses have been run only for the last day (day 7) and compared to the condition  REHshcontrol. * p < 0.05. c, d Kaplan–Meier survival 
curves from immunodeficient NOD/scid IL2 Rg null mice xenografted with 100,000 cells of REH,  REHshRUNX1,  REHshCBFA2T3−1,  REHshCBFA2T3−2 (C), or 
 REH+NHR2 (D) (n = 7–8 per group). The general condition of mice was monitored daily until experiment ended. Mantel‑Cox statistical tests compared 
to the condition  REHshcontrol. **p < 0.01, ***p < 0.001. e We propose the model in which CBFA2T3 acts as an activator of RUNX1 transcription activity 
and sustains cell proliferation. Presence of free NHR2 domain disrupts this activation complex and slows down proliferation
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bind together to regulate BCP-ALL proliferation, and 
also points out the importance of the role of CBFA2T3 in 
BCP-ALL proliferation.
Importantly, expression of NHR2 mimics the deple-
tion of RUNX1 and CBFA2T3 on the reduction of 
proliferation (Fig.  7b). Moreover, NHR2 reinforces 
the proliferation delay caused by RUNX1 depletion 
(Additional file 2: Fig. S3F). The difference in the pro-
liferation rate can be more attributed to moderate 
differences in cell cycle progression rather than apop-
tosis that is less than 2% in each of the four cell lines 
(Additional file 2: Fig. S3G) (data not shown for apop-
tosis). Mice xenografted with REH cells depleted for 
RUNX1 or CBFA2T3  (REHshCBFA2T3 and  REHshRUNX1) 
presented a longer survival compared to mice injected 
with  REHshcontrol cells (Fig.  7c) and similar results are 
observed with the expression of NHR2 (Fig. 7d). These 
results demonstrated that NHR2 mimics RUNX1 and 
CBFA2T3 depletion on proliferative phenotype. The 
NHR2 domain is an interesting candidate to coun-
teract CBFA2T3 activator effect on RUNX1-induced 
genes, at the level of the transcriptional activity of 
RUNX1 as well as at the level of cell proliferation. 
Our results suggest a model (Fig. 7e) whereby RUNX1 
recruits CBFA2T3 to chromatin, enabling a maximal 
transcriptional activity of the complex. Exogenous 
presence of NHR2 subdomain prevents the formation 
of this transcription complex, leading to RUNX1 tar-
get genes’ deregulations, and thus slowing down cell 
proliferation. The NHR2 peptide, or putative drugs 
mimicking NHR2, could be viewed as an interesting 
therapeutic tool to slow down BCP-ALL proliferation.
Discussion
In childhood ETV6-RUNX1 B-cell precursor acute 
lymphoblastic leukemia (BCP-ALL), the lymphoblasts 
present altered gene expression. Two genes are over-
expressed: RUNX1 and CBFA2T3, and their transcript 
levels are positively correlated pointing to a common 
regulator or a common activation loop. Accordingly, 
RUNX1 and CBFA2T3 proteins were previously identi-
fied as potential partners [22–24]. Therefore, we aimed 
at investigating the physical and functional interactions 
between RUNX1 and CBFA2T3, and their consequences 
for leukemogenesis. Our results confirmed that RUNX1 
and CBFA2T3 interact, and also showed that RUNX1 
binds RUNX1 promoter and − 2 kb CBFA2T3 enhancer, 
and drives the expression of both genes, defining a cross-
activating loop. We reported that the regulator CBFA2T3 
enhances RUNX1 transcriptional activity. Moreover, 
we demonstrated that addition of a CBFA2T3-domain 
NHR2 hampers the interaction between RUNX1 and 
CBFA2T3, dramatically inhibits RUNX1 transcription 
activity, and slows down BCP ALL-cell proliferation. 
Altogether, we demonstrated the existence of a new 
RUNX1 and CBFA2T3 driver-loop in ETV6-RUNX1 
leukemia.
The mechanisms of control of cell specification and 
differentiation rely on multimeric complexes containing 
transcription factors, coregulators, and additional non-
DNA binding components. The CBFA2T3 transcription 
regulator is found in such transcriptional complexes in 
many hematopoietic lineages. At the onset of blood cell 
specification, the SCL transcription factor forms a multi-
protein complex that contains CBFA2T3 and represses 
cardiac and paraxial cell lineages [36]. In erythroid cells, 
CBFA2T3 commonly represses GATA-1 function [37], 
and is critical for the Locus Control Region long-range 
interactions which support globin genes’ expression 
[38]]. In myeloid differentiation, CBFA2T3 interacts 
with PU1 to repress stem cell genes [22]. CBFA2T3 can 
also partner with PRDM14 on DNA and participates in 
T-ALL development [39]. Finally, in B-cell lineage, and in 
Diffuse Large B-cell Lymphoma in particular, CBFA2T3 
is reported to be part of the LMO2 complex regulating 
kinetochore function, chromosome assembly, and mito-
sis [40]. Our demonstration of the role of CBFA2T3 on 
the regulation of RUNX1 expression and function in 
preB-cells adds to the specificity of this transcription 
regulator.
In most of those CBFA2T3-multi-protein-containing 
complexes, CBFA2T3 is described as a repressor. Our 
data in BCP-ALL cells showed that, indeed, CBFA2T3 
is mainly bound to repressor effectors such as NCOR, 
HDACs and SIN3A. Yet, we also unveiled the binding of 
a fraction of CBFA2T3 to activators, including CBP and 
P300. Fujiwara et al. reported that the overexpression of 
CBFA2T3 in erythroid K562 cells leads to the upregula-
tion of 667 genes and the downregulation of 598 genes 
[41]. It is very likely that among the upregulated genes, 
there should be genes directly activated by CBFA2T3. 
The impact of CBFA2T3 on RUNX1 activity, and the con-
sistent observation that CBFA2T3 subdomain inhibitor 
results in a decrease in expression of RUNX1, CBFA2T3 
and c-KIT genes leads us to reconsider the paradigm 
of CBFA2T3 univocally viewed as a repressor. Here, 
we show that CBFA2T3 can strongly amplify RUNX1-
induced transcriptional activity. The exact mechanism 
of action, including the precise co-regulators, will be 
explored in future investigations. Yet, we clearly demon-
strated that CBFA2T3 binds RUNX1 transcription factor 
in an exogenous/overexpression model, but also demon-
strated that this binding exists at an endogenous steady-
state level in human preB cells, including BCP-ALL cell 
lines and BCP-ALL primary cells. These results are in 
agreement with previous reports in erythroid cells [23, 
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24], or in artificial overexpression model in HEK293T 
cells [22]. We provide the first demonstration that this 
RUNX1 and CBFA2T3 complex also occurs in preB-cells, 
and is responsible for a BCP-ALL driver loop.
We showed, by Chip-Seq, that CBFA2T3 and RUNX1 
interaction occurs at the chromatin level, and that 
CBFA2T3 has a strong impact on RUNX1 transcriptional 
activity, that is exerted on at least three genes, RUNX1, 
CBFA2T3 and c-KIT. CBFA2T3 and RUNX1 genes are 
also RUNX1 targets in myeloid cells [42] and in mixed-
phenotype acute leukemia [43]. It was also described in 
mice that Cbfa2t3 itself binds its own promoter in eryth-
roid cell lineage [44], and that RUNX1 binds its promoter 
in T-ALL cells [45].
We next questioned the role of the interaction between 
RUNX1 and CBFA2T3 and the self-activation loop 
between RUNX1 and CBFA2T3 in leukemogenesis. 
First, it is well known that alteration of each protein, 
RUNX1 and CBFA2T3, separately, causes hematologi-
cal malignancies. The fusion protein ETV6-RUNX1 sus-
tains BCP-ALL, RUNX1-ETO is highly frequent in acute 
myeloid leukemia, RUNX1-MECOM leads to myelodys-
plasia and acute myeloid leukemia CBFA2T3-GLIS2, and 
RUNX1-CBFA2T3 is found in acute megakaryoblastic 
leukemia [6, 7, 17, 46]. These fusion proteins rewire the 
normal transcriptional program. Globally, mouse models 
of RUNX1 overexpression do not lead directly to can-
cer by itself but increases cancer predisposition [47, 48]. 
CBFA2T3 is required to initiate Prdm14-induced T-acute 
lymphoblastic leukemia, demonstrating its oncogenic 
role [39]. Even though we demonstrated here an inter-
action between CBFA2T3 and ETV6-RUNX1 proteins, 
we did not obtain any evidence that CBFA2T3 could act 
directly onto ETV6-RUNX1 function. Rather, our data 
demonstrated the major combined role of CBFA2T3 
and RUNX1 proteins in ETV6-RUNX1-containing cells. 
Our data did not imply either that the presence of ETV6-
RUNX1 was required to observe CBFA2T3 and RUNX1 
interaction, yet, this interaction is important to sustain 
cell proliferation of ETV6-RUNX1 cells. Our findings fit 
perfectly well with the fact that normal RUNX1 is a driver 
in RUNX1-related leukemogenesis including t(12;21) 
ETV6-RUNX1 BCP-ALL, t(8;21) AML1-ETO and inv 
[16] CBFβ-SMMHC acute myeloid leukemia [6, 49]. This 
role may be exacerbated by the cross-activation loop 
between RUNX1 and CBFA2T3, where RUNX1 upregu-
lates CBFA2T3, which in turn enhances RUNX1 activ-
ity that promotes its own expression. We demonstrated 
that one mechanism by which CBFA2T3 and RUNX1 
promote leukemogenesis or maintain leukemia is by 
controlling cell proliferation. Our results are concordant 
with data from Steinauer et al. showing that downregula-
tion of CBFA2T3 arrests G1/S cell cycle progression and 
attenuates in vitro and in vivo proliferation of acute mye-
loid leukemia cells [50].
We can also question why ETV6-RUNX1 fusion pro-
tein could lead to positive correlation of RUNX1 and 
CBFA2T3 expression. ETV6-RUNX1 results from the 
fusion of a repressor (ETV6) with almost the entire 
RUNX1 which is an activator. It has never been formally 
demonstrated that ETV6-RUNX1 exclusively plays a 
repressive role on every promoter normally controlled 
by RUNX1, especially in preB-cells. PLA data in REH 
cells done with ETV6 antibody (thus targeting ETV6-
RUNX1 protein) show that ETV6-RUNX1 colocalizes 
with activators (CBP, P300) as well as repressors (NCOR, 
HDAC1) (personal data). At a functional level, in our 
hands, ETV6-RUNX1 reinforces the activation role of 
RUNX1 on RUNX1 promoter (Figure S1C), but not on 
the CBFA2T3 enhancer (Figure S1D) or on the RUNX1-
consensus motif repetition (Figure S1E) in luciferase 
promoter assays. This suggests that ETV6-RUNX1 can 
potentially play a similar activation role than RUNX1, 
depending on the chromatin context.
We showed that the interaction between CBFA2T3 
and RUNX1 mainly occurs by the NHR2 domain of 
CBFA2T3, which is also its oligomerization domain. The 
NHR2 domain is a protein–protein interaction motif, 
and is responsible for homo-oligomerization and dimeri-
zation among ETO family members [12, 13]. Ectopic 
intracellular expression of the NHR2 domain interferes 
with the RUNX1 and CBFA2T3 complex and decreases 
proliferation.
Several authors have been able to prevent ETO-fusion 
or CBFA2T3-fusion protein oligomerization, and impor-
tantly have demonstrated a reversion of the leukemic 
phenotype using a NHR2-mimicking protein or small 
molecule inhibitors mimicking the tetramerization inter-
face of NHR2, in particular with RUNX1-ETO fusion 
[14, 51–54] or CBFA2T3-GLIS2 fusion [55]. Our results 
are in line with these previous works, since we demon-
strated that exogenously expressed NHR2 domain pre-
vents RUNX1 and CBFA2T3 interaction, downregulates 
RUNX1 target genes’ expression and decreases BCP-
ALL cell proliferation. However, we cannot exclusively 
attribute this phenotype to disruption of RUNX1 and 
CBFA2T3 interactions. Indeed, CBFA2T3 interacts with 
other partners that can also participate in cell prolifera-
tion. Numerous binding partners have been reported for 
CBFA2T3, including transcription factors (DNA-binding 
partners) and chromatin modifiers (non-DNA-bind-
ing partners) [17]. Few data are available on CBFA2T3 
partners in B-cells, but the literature is richer for other 
hematopoietic lineages. CBFA2T3 depletion arrests cell 
cycle progression in acute myeloid leukemia cell lines and 
CD34 + hematopoietic stem and progenitor cells (HSPC) 
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[50, 56]. E-box proteins (E2A/HEB), TAL-1 complexes or 
GATA1 can be proposed to participate in this prolifera-
tion arrest [57, 58], in particular in the erythroid lineage 
[16, 59].
Conclusions
Altogether, we described an important activation loop 
between the transcription factor RUNX1 and the tran-
scription regulator CBFA2T3. We deciphered the inter-
action of RUNX1 with CBFA2T3, and demonstrated that 
addition of free  CBFA2T3NHR2 protein domain inhib-
its the interaction between RUNX1 and CBFA2T3, and 
results in reversion of leukemic phenotype by decreas-
ing BCP-ALL cell proliferation. Our findings unveil the 
role of CBFA2T3 also as a transcriptional activator for 
RUNX1 in human PreB lymphoblasts, and demonstrate 
the existence of a new RUNX1 and CBFA2T3 driver-loop 
in ETV6-RUNX1 BCP-ALL leukemia. Our findings open 
novel potential therapeutic approach for BCP-ALL.
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